Harnessing the integrated stress response for the treatment of multiple sclerosis

The Lancet Neurology

Volumn 15, Issue 4, 2016, Pages 434-443

  Way, Sharon W ^a   Popko, Brian ^a  

^a The University of Chicago Pritzker School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EUKARYOTE INITIATION FACTOR 2 ALPHA KINASE 3; GADD34 PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MYELIN; PROTEIN; PROTEIN KINASE; UNCLASSIFIED DRUG; INITIATION FACTOR 2; NEUROPROTECTIVE AGENT;

DISEASE COURSE; GENETIC MODEL; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; REMYELINIZATION; REVIEW; STRESS; ANIMAL; ENDOPLASMIC RETICULUM STRESS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ENDOPLASMIC RETICULUM STRESS; EUKARYOTIC INITIATION FACTOR-2; HUMANS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; OLIGODENDROGLIA; SIGNAL TRANSDUCTION;

EID: 84960480352     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00381-6     Document Type: Review

References (90)

1. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983, 308:173-180.
2. Paty DW, Li DK Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:662-667. the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
3. Costello K, Halper J, Kalb R, Skutnik L, Rapp R The use of disease-modifying therapies in multiple sclerosis: principles and current evidence 2015, Multiple Sclerosis Coalition, Cherry Hill, (accessed Dec 8, 2015). http://www.nationalmssociety.org/getmedia/5ca284d3-fc7c-4ba5-b005-ab537d495c3c/DMT_Consensus_MS_Coalition_color.
4. Charcot J-M Histologie de la sclérose en plaques. Gazette des Hospitaux 1868, 41:554-555.
5. Franklin RJ, ffrench-Constant C, Edgar JM, Smith KJ Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 2012, 8:624-634.
6. Kremer D, Küry P, Dutta R Promoting remyelination in multiple sclerosis: current drugs and future prospects. Mult Scler 2015, 21:541-549.
7. Hauser SL, Chan JR, Oksenberg JR Multiple sclerosis: prospects and promise. Ann Neurol 2013, 74:317-327.
8. Frohman EM, Racke MK, Raine CS Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955.
9. Trapp BD, Nave KA Multiple sclerosis: an immune or neurodegenerative disorder?. Annu Rev Neurosci 2008, 31:247-269.
10. Dutta R, Trapp BD Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 2011, 93:1-12.
11. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285.
12. Nave KA Myelination and support of axonal integrity by glia. Nature 2010, 468:244-252.
13. Morrison BM, Lee Y, Rothstein JD Oligodendroglia: metabolic supporters of axons. Trends Cell Biol 2013, 23:644-651.
14. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci 2000, 20:6404-6412.
15. Keirstead HS, Levine JM, Blakemore WF Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord. Glia 1998, 22:161-170.
16. Chang A, Tourtellotte WW, Rudick R, Trapp BD Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002, 346:165-173.
17. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG Multiple sclerosis. N Engl J Med 2000, 343:938-952.
18. Dutta R, Trapp BD Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol 2014, 27:271-278.
19. Stone S, Lin W The unfolded protein response in multiple sclerosis. Front Neurosci 2015, 9:264.
20. Donnelly N, Gorman AM, Gupta S, Samali A The eIF2α kinases: their structures and functions. Cell Mol Life Sci 2013, 70:3493-3511.
21. Ron D, Walter P Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007, 8:519-529.
22. Eizirik DL, Cardozo AK, Cnop M The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008, 29:42-61.
23. Cnop M, Foufelle F, Velloso LA Endoplasmic reticulum stress, obesity and diabetes. Trends Mol Med 2012, 18:59-68.
24. Baerwald KD, Popko B Developing and mature oligodendrocytes respond differently to the immune cytokine interferon-gamma. J Neurosci Res 1998, 52:230-239.
25. Baerwald KD, Corbin JG, Popko B Major histocompatibility complex heavy chain accumulation in the endoplasmic reticulum of oligodendrocytes results in myelin abnormalities. J Neurosci Res 2000, 59:160-169.
26. Kang J, Zhu L, Lu J, Zhang X Application of metabolomics in autoimmune diseases: insight into biomarkers and pathology. J Neuroimmunol 2015, 279:25-32.
27. Noga MJ, Dane A, Shi S, et al. Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis. Metabolomics 2012, 8:253-263.
28. Raphael I, Nalawade S, Eagar TN, Forsthuber TG T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 2015, 74:5-17.
29. Pierson E, Simmons SB, Castelli L, Goverman JM Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol Rev 2012, 248:205-215.
30. Steinman L No quiet surrender: molecular guardians in multiple sclerosis brain. J Clin Invest 2015, 125:1371-1378.
31. Voumvourakis KI, Antonelou RC, Kitsos DK, Stamboulis E, Tsiodras S TGF-β/BMPs: crucial crossroad in neural autoimmune disorders. Neurochem Int 2011, 59:542-550.
32. Trinh MA, Ma T, Kaphzan H, et al. The eIF2α kinase PERK limits the expression of hippocampal metabotropic glutamate receptor-dependent long-term depression. Learn Mem 2014, 21:298-304.
33. Lu PD, Jousse C, Marciniak SJ, et al. Cytoprotection by pre-emptive conditional phosphorylation of translation initiation factor 2. EMBO J 2004, 23:169-179.
34. Lassmann H Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci 2003, 206:187-191.
35. Aboul-Enein F, Lassmann H Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease?. Acta Neuropathol 2005, 109:49-55.
36. Stephenson E, Nathoo N, Mahjoub Y, Dunn JF, Yong VW Iron in multiple sclerosis: roles in neurodegeneration and repair. Nat Rev Neurol 2014, 10:459-468.
37. Law M, Saindane AM, Ge Y, et al. Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology 2004, 231:645-652.
38. Fern RF, Matute C, Stys PK White matter injury: ischemic and nonischemic. Glia 2014, 62:1780-1789.
39. Ghasemi M, Fatemi A Pathologic role of glial nitric oxide in adult and pediatric neuroinflammatory diseases. Neurosci Biobehav Rev 2014, 45:168-182.
40. Bogdan C Nitric oxide synthase in innate and adaptive immunity: an update. Trends Immunol 2015, 36:161-178.
41. Ciccarelli O, Barkhof F, Bodini B, et al. Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurol 2014, 13:807-822.
42. Schuh C, Wimmer I, Hametner S, et al. Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models. Acta Neuropathol 2014, 128:247-266.
43. Mansilla MJ, Montalban X, Espejo C Heat shock protein 70: roles in multiple sclerosis. Mol Med 2012, 18:1018-1028.
44. Turturici G, Tinnirello R, Sconzo G, et al. Positive or negative involvement of heat shock proteins in multiple sclerosis pathogenesis: an overview. J Neuropathol Exp Neurol 2014, 73:1092-1106.
45. Pender MP The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 2011, 17:351-367.
46. Virtanen JO, Jacobson S Viruses and multiple sclerosis. CNS Neurol Disord Drug Targets 2012, 11:528-544.
47. Mháille AN, McQuaid S, Windebank A, et al. Increased expression of endoplasmic reticulum stress-related signaling pathway molecules in multiple sclerosis lesions. J Neuropathol Exp Neurol 2008, 67:200-211.
48. McMahon JM, McQuaid S, Reynolds R, FitzGerald UF Increased expression of ER stress- and hypoxia-associated molecules in grey matter lesions in multiple sclerosis. Mult Scler 2012, 18:1437-1447.
49. Cunnea P, Mháille AN, McQuaid S, Farrell M, McMahon J, FitzGerald U Expression profiles of endoplasmic reticulum stress-related molecules in demyelinating lesions and multiple sclerosis. Mult Scler 2011, 17:808-818.
50. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
51. Allen IV, McQuaid S, Mirakhur M, Nevin G Pathological abnormalities in the normal-appearing white matter in multiple sclerosis. Neurol Sci 2001, 22:141-144.
52. Deslauriers AM, Afkhami-Goli A, Paul AM, et al. Neuroinflammation and endoplasmic reticulum stress are coregulated by crocin to prevent demyelination and neurodegeneration. J Immunol 2011, 187:4788-4799.
53. Ni Fhlathartaigh M, McMahon J, Reynolds R, et al. Calreticulin and other components of endoplasmic reticulum stress in rat and human inflammatory demyelination. Acta Neuropathol Commun 2013, 1:37.
54. Traugott U, Lebon P Multiple sclerosis: involvement of interferons in lesion pathogenesis. Ann Neurol 1988, 24:243-251.
55. Lin W, Harding HP, Ron D, Popko B Endoplasmic reticulum stress modulates the response of myelinating oligodendrocytes to the immune cytokine interferon-gamma. J Cell Biol 2005, 169:603-612.
56. Lin W, Kemper A, McCarthy KD, et al. Interferon-gamma induced medulloblastoma in the developing cerebellum. J Neurosci 2004, 24:10074-10083.
57. Harding HP, Zhang Y, Ron D Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999, 397:271-274.
58. Harding HP, Zeng H, Zhang Y, et al. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell 2001, 7:1153-1163.
59. Hussien Y, Cavener DR, Popko B Genetic inactivation of PERK signaling in mouse oligodendrocytes: normal developmental myelination with increased susceptibility to inflammatory demyelination. Glia 2014, 62:680-691.
60. Lin W, Bailey SL, Ho H, et al. The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. J Clin Invest 2007, 117:448-456.
61. Lin W, Lin Y, Li J, et al. Oligodendrocyte-specific activation of PERK signaling protects mice against experimental autoimmune encephalomyelitis. J Neurosci 2013, 33:5980-5991.
62. Gow A, Wrabetz L CHOP and the endoplasmic reticulum stress response in myelinating glia. Curr Opin Neurobiol 2009, 19:505-510.
63. Rutkowski DT, Kaufman RJ That which does not kill me makes me stronger: adapting to chronic ER stress. Trends Biochem Sci 2007, 32:469-476.
64. Sano R, Reed JC ER stress-induced cell death mechanisms. Biochim Biophys Acta 2013, 1833:3460-3470.
65. Southwood CM, Garbern J, Jiang W, Gow A The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease. Neuron 2002, 36:585-596.
66. Novoa I, Zeng H, Harding HP, Ron D Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol 2001, 153:1011-1022.
67. Lin W, Kunkler PE, Harding HP, Ron D, Kraig RP, Popko B Enhanced integrated stress response promotes myelinating oligodendrocyte survival in response to interferon-gamma. Am J Pathol 2008, 173:1508-1517.
68. Boyce M, Bryant KF, Jousse C, et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005, 307:935-939.
69. Tsaytler P, Harding HP, Ron D, Bertolotti A Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 2011, 332:91-94.
70. Way SW, Podojil JR, Clayton BL, et al. Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic. Nat Commun 2015, 6:6532.
71. Miller SD, Karpus WJ, Davidson TS Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol 2010, 88:15.1.
72. Hisahara S, Araki T, Sugiyama F, et al. Targeted expression of baculovirus p35 caspase inhibitor in oligodendrocytes protects mice against autoimmune-mediated demyelination. EMBO J 2000, 19:341-348.
73. Mc Guire C, Volckaert T, Wolke U, et al. Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination. J Immunol 2010, 185:7646-7653.
74. Lin W, Kemper A, Dupree JL, Harding HP, Ron D, Popko B Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain 2006, 129:1306-1318.
75. Lin Y, Huang G, Jamison S, et al. PERK activation preserves the viability and function of remyelinating oligodendrocytes in immune-mediated demyelinating diseases. Am J Pathol 2014, 184:507-519.
76. Franklin RJ, Goldman SA Glia disease and repair-remyelination. Cold Spring Harb Perspect Biol 2015, 7:a020594.
77. Matsushima GK, Morell P The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001, 11:107-116.
78. Novoa I, Zhang Y, Zeng H, Jungreis R, Harding HP, Ron D Stress-induced gene expression requires programmed recovery from translational repression. EMBO J 2003, 22:1180-1187.
79. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 2009, 625:234-246.
80. Young KM, Psachoulia K, Tripathi RB, et al. Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin remodeling. Neuron 2013, 77:873-885.
81. Watkins TA, Emery B, Mulinyawe S, Barres BA Distinct stages of myelination regulated by gamma-secretase and astrocytes in a rapidly myelinating CNS coculture system. Neuron 2008, 60:555-569.
82. Das I, Krzyzosiak A, Schneider K, et al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science 2015, 348:239-242.
83. Baum T, Shropshire AT Studies on the centrally mediated hypotensive activity of guanabenz. Eur J Pharmacol 1976, 37:31-44.
84. Nguyen PH, Hammoud H, Halliez S, et al. Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost α2-adrenergic receptor agonistic activity. ACS Chem Neurosci 2014, 5:1075-1082.
85. Ben-Hur T, Fainstein N, Nishri Y Cell-based reparative therapies for multiple sclerosis. Curr Neurol Neurosci Rep 2013, 13:397.
86. Czepiel M, Boddeke E, Copray S Human oligodendrocytes in remyelination research. Glia 2015, 63:513-530.
87. Tanner DC, Campbell A, O'Banion KM, Noble M, Mayer-Pröschel M cFLIP is critical for oligodendrocyte protection from inflammation. Cell Death Differ 2015, 22:1489-1501.
88. McClorey G, Wood MJ An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr Opin Pharmacol 2015, 24:52-58.
89. DeVos SL, Miller TM Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics 2013, 10:486-497.
90. Boettcher M, McManus MT Choosing the right tool for the job: RNAi, TALEN, or CRISPR. Mol Cell 2015, 58:575-585.